Roche announced that Elecsys pTau217, the first blood test designed to signal and rule out Alzheimer's disease, has received CE Mark clearance for use in Europe, offering a faster and simpler diagnostic tool for millions of patients and potentially reducing the burden on healthcare systems. #Alzheimers #BloodTest #HealthcareInnovation #EU #CH #US
Roche has received clearance for Elecsys pTau217, the first blood test designed to diagnose and rule out Alzheimer's disease in Europe, which promises faster diagnoses for millions of patients by detecting levels of a protein linked to the disease. #AlzheimersDisease #BloodTest #HealthcareInnovation #EU #CH #US
Roche has announced that the Elecsys pTau217 blood test, developed in collaboration with Eli Lilly and Company and now cleared for use in Europe, offers a rapid and effective method for diagnosing or ruling out Alzheimer's disease, potentially aiding millions of patients while reducing the burden on healthcare systems. #Alzheimers #BloodTest #Healthcare #EU #CH #US
Roche announced the European clearance of Elecsys pTau217, the first blood test designed to diagnose and rule out Alzheimer's disease, which offers a quicker diagnostic tool for millions of patients and aims to simplify the diagnostic process for physicians by indicating the likelihood of Alzheimer’s presence based on pTau217 protein levels. #Alzheimers #HealthcareInnovation #BloodTest #EU #CH #US
Roche announced the approval of Elecsys pTau217, the first blood test designed to signal and rule out Alzheimer's disease, which is now cleared for use in Europe, offering a faster and simpler diagnostic tool that can significantly improve early detection for patients and alleviate pressure on healthcare systems. #Alzheimers #BloodTest #HealthcareInnovation #EU #CH
